Results 1 to 10 of about 110,880 (264)

Tacrolimus Intrapatient Variability After Switching From Immediate or Prolonged-Release to Extended-Release Formulation, After an Organ Transplantation

open access: yesFrontiers in Pharmacology, 2021
Background and Purpose: Several formulations of tacrolimus are available, but evidence of the benefit of changing to the most recent formulations is lacking. Tacrolimus intra-patient variability (tacrolimus IPV) is an emerging risk factor associated with
Arnaud Del Bello   +11 more
doaj   +1 more source

Human kidney organoids model the tacrolimus nephrotoxicity and elucidate the role of autophagy [PDF]

open access: yesThe Korean Journal of Internal Medicine, 2021
Background/Aims Tacrolimus has been used as an immunosuppressive agent in organ transplantation. Despite the therapeutic benefits, tacrolimus’s use is limited due to its nephrotoxicity.
Jin Won Kim   +12 more
doaj   +1 more source

A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients

open access: yesClinical and Translational Science, 2022
A high intrapatient variability (IPV) in tacrolimus exposure is a risk factor for poor long‐term outcomes after kidney transplantation. The main objective of this trial was to investigate whether tacrolimus IPV decreases after switching patients from ...
Kim L. W. Bunthof   +8 more
doaj   +1 more source

Tacrolimus monitoring in hair samples of kidney transplant recipients

open access: yesFrontiers in Medicine, 2023
BackgroundCalcineurin inhibitors, including tacrolimus, remain a cornerstone of immunosuppressive therapy after kidney transplantation. However, the therapeutic window is narrow, and nephrotoxic side effects occur with overdose, while the risk of ...
Alexander Born   +5 more
doaj   +1 more source

Tacrolimus-induced neurotoxicity from bipolar disorder to status epilepticus under the therapeutic serum level: a case report

open access: yesBMC Neurology, 2021
Background Tacrolimus is a macrolide immunosuppressant widely used to prevent rejection after solid organ transplantation. In general, adverse events of tacrolimus occur more often as the concentration of tacrolimus in the blood increases.
Bora Jin, Ga Yeon Kim, Sang-Myung Cheon
doaj   +1 more source

Clinical association between tacrolimus intra-patient variability and liver transplantation outcomes in patients with and without hepatocellular carcinoma

open access: yesScientific Reports, 2022
Tacrolimus is the mainstay of immunosuppression in liver transplantation to prevent rejection. However, the clinical use of tacrolimus is complicated by its narrow therapeutic window and significant intra-patient variability (IPV). High tacrolimus IPV is
Hyun Jeong Kim   +4 more
doaj   +1 more source

Intravenous tacrolimus is a superior induction therapy for acute severe ulcerative colitis compared to oral tacrolimus

open access: yesBMC Gastroenterology, 2021
Background Intravenous corticosteroid is the mainstay for managing acute severe ulcerative colitis, but one-third of patients do not respond to intravenous corticosteroid.
Hiromichi Shimizu   +10 more
doaj   +1 more source

Tacrolimus Concentration Is Effectively Predicted Using Combined Clinical and Genetic Factors in the Perioperative Period of Kidney Transplantation and Associated with Acute Rejection

open access: yesJournal of Immunology Research, 2022
Background. Tacrolimus has unpredictable pharmacokinetic (PK) characteristics, which are partially attributed to CYP3A5 polymorphism. The potential effects of clinical factors in the postoperative period of transplantation on tacrolimus PK and those of ...
Fang Cheng   +5 more
doaj   +1 more source

Tacrolimus analysis: A comparison of different methods and matrices [PDF]

open access: yes, 1995
We determined the trough blood and plasma concentrations of tacrolimus from the day of transplantation through 30 days posttransplantation in four liver and four kidney transplant patients by three different methods.
Chao, J   +7 more
core   +1 more source

Home - About - Disclaimer - Privacy